DMT210: Ph II DMT210-003 started

Dermata began the double-blind, vehicle-controlled, U.S. Phase II DMT210-003 trial to evaluate DMT210 5% topical gel twice daily for 12 weeks in about 104 patients. Dermata has exclusive, worldwide ri...